Andrew Hack - Jun 10, 2021 Form 4 Insider Report for DYNAVAX TECHNOLOGIES CORP (DVAX)

Role
Director
Signature
/s/ Andrew Hack
Stock symbol
DVAX
Transactions as of
Jun 10, 2021
Transactions value $
$0
Form type
4
Date filed
6/11/2021, 05:23 PM
Previous filing
Jun 2, 2021
Next filing
Jun 15, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding DVAX Common Stock 8.53M Jun 10, 2021 See footnotes F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DVAX Warrants (Right to Buy) Sale -2.92M -100% 0 Jun 10, 2021 Common Stock 2.92M $4.50 See footnotes F1, F2, F3
holding DVAX Series B Convertible Preferred Stock 4.14M Jun 10, 2021 Common Stock 4.14M $0.00 See footnotes F1, F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents securities held directly by Bain Capital Life Sciences Fund, L.P. ("BCLS") and BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS, the "Bain Capital Life Sciences Entities").
F2 Bain Capital Life Sciences Investors, LLC ("BCLSI") is the ultimate general partner of BCLS and governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Hack is a Managing Director of BCLSI. By virtue of the relationships described in this footnote, Dr. Hack may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Dr. Hack disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
F3 On June 10, 2021, the Bain Capital Life Sciences Entities sold warrants to purchase an aggregate of 2,916,250 shares of common stock of the Issuer for aggregate consideration of $11,839,914.
F4 Each share of Series B Convertible Preferred Stock is convertible, at the option of the holder, into 1,000 shares of the Issuer's common stock and has no expiration date. The Series B Convertible Preferred Stock is not convertible if, as a result of such conversion, the holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of the Issuer's common stock then issued and outstanding immediately after giving effect to the conversion.